Indaptus Therapeutics, Inc. Common Stock
INDPIndaptus Therapeutics, Inc. is a biotechnology company focused on developing innovative immuno-oncology and infectious disease therapies. The company leverages its proprietary INDP-001 platform to create targeted treatments aimed at stimulating the immune system to fight cancer and infectious diseases. Headquartered in the United States, Indaptus aims to advance therapies that address unmet medical needs through cutting-edge research and development.
Company News
Abbott Cooper PLLC is investigating potential fiduciary duty violations by the board of Indaptus Therapeutics in connection with a private placement of preferred stock. The investigation targets stockholders who held shares prior to December 22, 2025.
Indaptus Therapeutics, a clinical-stage biotechnology company, highlights its accomplishments in 2024 and outlines its strategic goals for 2025, including the launch of a combination trial with BeiGene's tislelizumab and the expansion of its Decoy20 clinical trial.
Indaptus Therapeutics presented positive interim safety data from a Phase 1 trial of its lead compound Decoy20, which showed an acceptable safety profile and signs of anti-tumor activity. The company plans to combine Decoy20 with a PD-1 inhibitor in a new cohort.
Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of De...
Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly
